Abstract
We investigated clinical outcome of asymptomatic coronavirus disease 2019 (COVID-19) and identified risk factors associated with high patient mortality using Korean nationwide public database of 5,621 hospitalized patients. The mortality rate and admission rate to intensive care unit were compared between asymptomatic and symptomatic patients. The prediction model for patient mortality was developed through risk factor analysis among asymptomatic patients. The prevalence of asymptomatic COVID-19 infection was 25.8%. The mortality rates were not different between groups (3.3% vs. 4.5%, p=0.17). However, symptomatic patients were more likely to receive ICU care compared to asymptomatic patients (4.1% vs. 1.0%, p<0.0001). The age-adjusted Charlson comorbidity index score (CCIS) was the most potent predictor for patient mortality in asymptomatic patients. The clinicians should predict the risk of death by evaluating age and comorbidities but not the presence of symptoms.
Article Summary Line Since asymptomatic patients have similar mortality rate with symptomatic patients, the clinicians should not classify clinical severity according to initial presence of symptom.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no specific funding for this work. The authors declare no competing interests.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The present study protocol was reviewed and approved by the Institutional Review Board of the Kangnam Sacred Heart Hospital, Seoul, Korea (HKS 2020-06-025). The informed consent was waived due to retrospective nature of the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Identifiable patient level data from this cohort study are not available to the public.